BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$10.29M. The highest annual figure on record is -$10.29M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.29M | – |
| FY2024 | Dec 31, 2024 | -$20.41M | – |
| FY2023 | Dec 31, 2023 | -$49.69M | – |
| FY2022 | Dec 31, 2022 | -$29.16M | – |
| FY2021 | Dec 31, 2021 | -$24.78M | – |
| FY2020 | Dec 31, 2020 | -$22.93M | – |
| FY2019 | Dec 31, 2019 | -$28.11M | – |
| FY2018 | Dec 31, 2018 | -$25.61M | – |
| FY2017 | Dec 31, 2017 | -$25.24M | – |
| FY2016 | Dec 31, 2016 | -$16.51M | – |
| FY2015 | Dec 31, 2015 | -$16.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.48M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.19M | – |
See a number that looks wrong?